Literature DB >> 23239585

On the practical application of mixed effects models for repeated measures to clinical trial data.

Scott W Andersen1, Brian A Millen.   

Abstract

The use of mixed effects models for repeated measures (MMRM) for clinical trial analyses has recently gained broad support as a primary analysis methodology. Some questions of practical implementation detail remain, however. For example, whether and how to incorporate clinical trial data that is collected at nonprotocol-specified timepoints or clinic visits has not been systematically studied. In this paper, we compare different methods for applying MMRM to trials wherein data is available at protocol-specified timepoints, as well as nonprotocol-specified timepoints due to patient early discontinuation. The methods under consideration included observed case MMRM, per protocol visits MMRM, interval last observation carried forward (LOCF) MMRM, and a hybrid of the per protocol visits and interval LOCF MMRM approaches. Simulation results reveal that the method that best controls the type I error rate is the per protocol visits method. This method is also associated with the least precision among the competing methods. Thus, in confirmatory clinical trials wherein control of type I error rates is critical, per protocol visits MMRM is recommended. However, in exploratory trials where strict type I error control is not as critical, one may prefer interval LOCF MMRM due to its increased precision. Points to consider with respect to both study design (e.g., assigning schedule of events) and subsequent analysis are offered.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23239585     DOI: 10.1002/pst.1548

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  3 in total

1.  Prognostic value of perioperative NT-proBNP after corrective surgery for pediatric congenital heart defects.

Authors:  Fangqin Lin; Lingling Zheng; Yanqin Cui; Weidan Chen; Ramit Kumar Gupta; Huixian Li; Xinxin Chen; Huimin Xia; Huiying Liang
Journal:  BMC Pediatr       Date:  2019-12-16       Impact factor: 2.125

2.  Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial.

Authors:  Farida F Berkhof; Nynke E Doornewaard-ten Hertog; Steven M Uil; Huib A M Kerstjens; Jan W K van den Berg
Journal:  Respir Res       Date:  2013-11-14

3.  Dose-Response Mixed Models for Repeated Measures - a New Method for Assessment of Dose-Response.

Authors:  Gustaf J Wellhagen; Bengt Hamrén; Maria C Kjellsson; Magnus Åstrand
Journal:  Pharm Res       Date:  2020-07-31       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.